

## Year Ended 30 June 2020 Highlights

### Funds Applied

During the year ended 30 June 2020 the Board approved Public Health Entity (PHE) budget requests of \$10.8M, against which \$6.6M was spent by PHEs. This was advanced for various purposes such as:

- Research and PHE-staff Professional Development;
- Conferences and Training;
- Equipment (research and non-research); and
- Other expenditure such as Volunteer support.

A number of PHE spending initiatives that were budgeted for did not proceed, or were delayed as a result of the effects of the Covid-19 pandemic.

More details of expenditure funded can be found in pages 22-23 of the 2019-20 HSCGB Annual Report.

### Highlights of Funds Applied

Set out on pages 29 and 30 of the HSCGB Annual Report are some of the projects and programs that have been funded in 2019-20. An example of the research being funded includes research in the Beat Cancer Project using advanced T-cell therapy for leukaemia and glioblastoma and, cardiovascular outcomes of transcatheter aortic valve replacement (TAVR). Other items funded include the PINI Program which is the Preventing Neurological Injury Initiative with preterm infants, various equipment purchases and various support to the hospital volunteer programs.

### Income

Total income for 2019-20 of \$6.8M was 57% lower than the previous year. The Covid-19 pandemic had a significant effect on investment markets during the year, with decreased investment values and in turn adversely lowered investment returns for the year. While bequest income was slightly higher in 2019-20 (37% higher), all other income lines were lower than the previous year i.e. (investment revenue down 102%; rental and other revenue down 3%; and gifts and donations other than bequests down 5%). More details of this income can be found in the Statement of Comprehensive Income and Notes 4 and 8 in the audited financial statements that are part of the Annual Report.

Of the \$4.5M received in Bequests and other Gifts and Donations:

- 81% was received for RAH and TQEH;
- 9% for WCH;
- 9% for SA Pathology and Hanson Centre;
- 0.3% for Flinders and Noarlunga Hospitals; and
- 0.7% for Whyalla and other PHEs

The investment performance for the portfolios under management for the Board was:

Portfolio	1 yr return	3 yr pa return
HSCGB Pool	-0.3%	4.3%
Martin Estate	3.5%	7.1%
The Ray & Shirl Norman Cancer Research Trust	-1.1%	5.1%
DE Brown Charitable Trust	*0.2%	*4.1%

\* Funds SA reported earnings rate

More details of income for the year can be found in pages 14-15 of the 2019-20 HSCGB Annual Report.

At 30 June 2020, a total of \$141.3M (a decrease of \$400,000 from the previous year) was held by the Board. Of this sum 83% was held on behalf of the RAH and TQEH. More details can be found at Note 10 of the financial statements as contained in the 2019-20 HSCGB Annual Report.

The activities of the Board are audited by the Auditor General. His report can be found at page 38 of the 2019-20 HSCGB Annual Report.